A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Active, not recruiting · NCT07047118 · Registry updated 2026-10-09Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Prostatic Cancer, Castration-Resistant, Prostatic Neoplasms, Castration-Resistant, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 2 | 2026-10-09 | NCT07047118 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Novartis Pharmaceuticals | 432 |
10 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| City of Hope National Medical | Duarte | United States | 5 |
| Indiana University | Indianapolis | United States | 160 |
| Massachusetts General Hospital | Boston | United States | 1015 |
| NYU Laura and Isaac Perlmutter Cancer Center | New York | United States | 3 |
| Providence Saint Johns Health Ctr | Santa Monica | United States | 4 |
| Rocky Mountain Cancer Centers | Denver | United States | 26 |
| Univ of Pittsburgh Cancer Institute | Pittsburgh | United States | 2 |
| Urology San Antonio | San Antonio | United States | 17 |
| XCancer Omaha LLC | Omaha | United States | 3 |
| Yale University School Of Medicine | New Haven | United States | 22 |